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ORTHOCLONE OKT3 in Treatment of Allografts 
Rejected Under Cyclosporine-Steroid Therapy 
T. E. Starzl and J. J. Fung 
I N 1899, Metchnikoff first conceived of 
specific therapy with antilymphocyte 
globulin (ALG) compounds.! Research was 
carried out sporadically in Europe, mostly by 
Swiss immunologists. Antilymphocyte serum 
(ALS) was first used to prevent skin graft 
rejection in experimental animals by Waks-
man et al2 and subsequently by Woodruff and 
Anderson.3 
ALG was first used clinically in 1966.4 Its 
value was promptly confirmed in a number of 
centers in Europe, Australia, and the United 
States. Yet while ALS and ALG demon-
strated potent immunosuppressive qualities, 
they could not be standardized. Moreover, 
lack of predictability of response greatly lim-
ited their use. 
The original antihuman ALGs were pre-
pared after immunization of horses, rabbits, 
or goats with human lymphoid tissue.5 The 
active fraction, IgG, was then extracted and 
used for intramuscular or intravenous (IV) 
injection. These primitive ALGs often con-
tained antibodies that reacted to contaminat-
ing blood elements as well as other nonrele-
vant antigens. 
With the development of hybridoma tech-
nology, an important refinement of the origi-
nal ALG concept became possible.6 Kung et 
ar reported in 1979 the development of mono-
clonal antibody, ORTHOCLONE OKT3 
(Ortho Pharmacentical Corp., Raritan, NJ), 
using the hybridoma technology. ORTHO-
CLONE OKT3 is a standardizable substance 
with defined specificity and greater than 95% 
relevant protein. 
ORTHOCLONE OKT3 was introduced 
clinically by Cosimi et al in 1981.8 Most 
clinical trials with ORTHOCLONE OKT3 
have been for the treatment of renal rejection 
occurring despite immunosuppression with 
azathioprine and prednisone. With the 
expanding use of cyclosporine, the way in 
which ORTHOCLONE OKT3 fits in with 
cyclosporine-steroid therapy is an important 
issue. Initially, there was some speculation, 
based largely on hypothetical grounds, that 
ORTHOCLONE OKT3 might be pharmaco-
logically incompatible with cyclosporine. That 
notion has been largely dispelled by practical 
experience. The aim of our studies was to 
determine the usefulness of ORTHOCLONE 
OKT3, in conjunction with cyclosporine and 
steroids. 
METHODS 
Sixty-two patients were treated with ORTHOCLONE 
OKT3, including 52 liver and ten kidney allograft recip· 
ients whose baseline immunosuppression was with cyclo· 
sporine and steroids. ORTHOCLONE OKT3 treatment 
was initiated in all renal transplant recipients, because 
rejection continued in spite of cyclosporine and high-dose 
steroid therapy. The initial 18 liver recipients were part of 
a randomized trial comparing ORTHOCLONE OKT3 
and high-dose steroids, whereas the remaining 34 liver 
patients received ORTHOCLONE OKT3 after failing to 
respond to a steroid recycle. Adults were given 5 mg IV of 
ORTHOCLONE OKT3 daily for ten to 14 days. Small 
pediatric recipients were given half the adult dose; in 
some small infants, one fifth of the adult dose was used. 
Thus, doses were not administered completely on a body 
weight basis. 
Volume overload was corrected if present. In addition, 
since symptoms are seen generally within the first few 
days of treatment, when lymphocyte destruction is 
greatest, premedication with hydrocortisone and diphen-
hydramine was given. Development of anaphylactoid 
reactions (pulmonary edema) is heralded by respiratory 
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symptoms that mimic asthma. As a precaution, when 
patients complained of shortness of breath, even without 
objective signs of distress, they were moved into the 
intensive care area, as they may have required intubation 
and ventilatory support as well as resuscitation. Epineph-
rine administered IV was the most effective drug for 
severe distress. 
RESULTS WITH RENAL TRANSPLANTATION 
Eight of ten steroid-resistant kidney recip-
ients responded to monoclonal treatment: four 
partially and four completely. Failures were in 
patients who had vascular (antibody-
mediated) rejection. This was documented 
pathologically in one of two failures; in the 
other, there also was cellular rejection. Four 
patients achieved stable but abnormal func-
tion, although two eventually lost their kidney 
grafts. Overall, all ten patients would proba-
bly have lost their grafts; but with ORTHO-
CLONE OKT3, six were salvaged, four with 
completely normal function. 
Figure 1 shows the course of a patient who 
started the postoperative period with an acute 
tubular necrosis, but began to recover with 
delayed diuresis. Diuresis was cut off at the 
onset of rejection, which could not be reversed 
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Fig 1. Clinical course of cadaveric kidney recipient 
whose graft underwent initial period of acute tubular 
necrosis, with beginning subsequent diuresis inter-
rupted by rejection. Arrows ~ administration of 1 g 
methylprednisolone. 
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or controlled with high-dose steroid therapy. 
ORTHOCLONE OKT3 therapy was ini-
tiated on day 25 posttransplant, and there was 
immediate reversal of rejection and recovery 
of renal function within a few days. Immuno-
suppressive therapy with cyclosporine was not 
reduced in this case. Steroid therapy was left 
at baseline level. 
In some patients, monoclonal treatment 
was used as a window through which baseline 
immunosuppressive therapy could be in-
creased or decreased according to what was 
believed optimal for maintenance; this is per-
haps the key to avoiding rerejection. 
Minor infections occurred during the treat-
ment period in 40% of patients, usually a viral 
infection (most commonly herpes simplex 
reactivation). There was no mortality. 
RESULTS WITH LIVER TRANSPLANTATION 
Initially, a randomized trial on treatment of 
hepatic rejection was conducted in which 
ORTHOCLONE OKT3 and high-dose ste-
roids were administered. Our conclusion was 
that ORTHOCLONE OKT3 was superior to 
steroid therapy. Of seven patients randomized 
to receive ORTHOCLONE OKT3, six had 
full recovery of hepatic function. Rescue of 
ORTHOCLONE OKT3 treatment failures 
would have been with high-dose steroid thera-
py; this was not required, however, as there 
was no recurrence of rejection in ORTHO-
CLONE OKT3 responders. 
Eleven patients were randomized to steroid 
therapy; four had reversal of rejection, while 
seven remained resistant to steroid therapy 
and required rescue with ORTHOCLONE 
OKT3. ORTHOCLONE OKT3 was success-
ful in reversing the rejection in six of the seven 
patients. 
As the trial progressed, concerns were 
raised that randomization might not be appro-
priate. One possibility was that ORTHO-
CLONE OKT3 was being used in cases which 
might have responded to increased steroids. In 
cases of severe rejection, it was possible that 
ORTHOCLONE OKT3 was being withheld 
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Fig 2. Current protocol for treatment of suspected 
rejection . 
when it could have been life-saving, in order to 
adhere to the study protocol. 
For these reasons, randomization was 
stopped in favor of the protocol described in 
Fig 2. Patients who entered the study had liver 
dysfunction of unexplained etiology (technical 
causes were ruled out). Workup included a 
percutaneous biopsy, which allowed proof of 
cell-mediated rejection (Fig 3A). If the biopsy 
demonstrated rejection, a steroid recycle was 
tried. This caused a response in some cases, 
but in the event of no response, OR THO-
CLONE OKT3 therapy was given for ten to 
14 days. Thus, a protocol of rescue of steroid-
resistant patients was arrived at. In these 
patients, cellular rejection was concentrated 
around the portal tracts. The percutaneous 
b:upsies allowed proof of improvement (Fig 
3B) . Most patients started on ORTHO-
CLONE OKT3 were rebiopsied after comple-
tion of therapy. The pathologic correlation of 
improvement with ORTHOCLONE OKT3 
was virtually absolute.9 
The results are stratified into three groups. 
Group 1 patients were given ORTHO-
CLONE OKT3 therapy during the first nine 
postoperative days. They had poor hepatic 
function in the early postoperative period . 
939 
Fig 3. (A) Histologic findings of cellular rejection 
typical in group 2 liver patients consist of portal mono-
nuclaar cell infiltration with damage to bile duct epithe-
lium and endothelium of vessels . (8) Improvement of 
histologic findings after ORTHOCLONE OKT3 therapy. 
Note marked decresse of inflammatory cells . 
Renal failure, a common complication in 
patients with endstage liver disease and a 
complication of cyclosporine treatment, was 
also common. Rejection was suspected, and in 
15 of the 18 patients, rejection was proven by 
biopsy, although not always at the exact 
moment ORTHOCLONE OKT3 therapy 
was started. Biopsies were not carried Oilt at 
this time in cases in which severe liver failure 
led to such poor coagulation that the proce-
dure was not safe. 
Group 2 consisted of 22 patients who were 
between 10 and 90 days postoperative. In this 
group there was no real ambiguity in ascribing 
hepatic dysfunction to rejection, since biopsies 
could be obtained routinely. 
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Group 3 consisted of 12 patients treated 
beyond 90 days, in whom an element of 
chronic rejection may have been present; con-
fusing perioperative factors characteristic of 
group I patients, however, were not present. 
Results are summarized in Table 1. In 
group I patients in whom renal failure in 
combination with liver dysfunction was com-
mon, ORTHOCLONE OKT3 therapy al-
lowed lowering of potentially nephrotoxic 
cyclosporine doses. An example of a patient 
who had poor primary hepatic graft function 
is shown in Fig 4. The patient's bilirubin 
began at a high level and continued to rise 
concurrent with rapidly advancing renal fail-
ure. However, when ORTHOCLONE OKT3 
therapy was started, oral cyclosporine was 
continued, and IV cyclosporine stopped, blood 
levels of cyclosporine leveled off adequately. 
Group I patients had the poorest record: 
33% had a full response; 39% had a partial 
response, and approximately 30% had no 
response (Table 1). Yet, incongruously, the 
impact of ORTHOCLONE OKT3 on liver 
transplantation should be greatest for group 
I-type patients, because this is the group that. 
will have a high mortality rate if something 
decisive cannot be done, such as rescue with 
ORTHOCLONE OKT3 therapy. 
In group 2, better than 90% of patients had 
reversal of rejection (Table I). Three quarters 
of the patients had a full response with return 
of normal hepatic function. 
In group 3, almost half of the patients 
treated for more than 3 months had a full 
response, even though in many there was 
undoubtedly an element of chronic rejection; 
Table 1. Results of ORTHOCLONE OKT3 Therapy in 
Liver Transplant Recipients 
Long-term 
Response ('l6) Graft Function-
None Partial Full ('l6) 
Overall 22 25 53 71 
Group 1 28 39 33 66 
Group 2 9 18 73 81 
Group 3 33 25 42 52 
*Follow-up 7.2 ± 1.7 mo. 
STARZl AND FUNG 
''';''' }~~-====---==-~ -----~ ! 
Brk:::~! ~ (mg/d!) 
50 
D~~ ~~i=======:g===== 
lOre I TBIl (mgld" : ___ 
··~~~~i 
OKT3 (mg/d) g LB mrf:!/pd~l1e 1M~~i~"~";:;:;";:;:;";:;:;"D~D;:;:;";:;:;":;::;":;::;";:;:;";:;:;DK= •• ;:;:;.= .:;::; .. ;:;:; .. ::;; .. ::;; .. ::;; .. ;:;:; .. ;:;:;--=::; 
Steroid Bolus O~ ijf -
(g/d) :"0 "----:-PM::---S::I-M-~9MI----1O-M---IRM::---IU-M-O-IM:---I-gO4M 
DAYS POST-TRANSPLANT 
Fig 4. Clinical course of liver recipient whose 
ORTHOCLONE OKT3 course was started after nine 
days. in part because renal failure precluded giving 
therapeutic doses of cyclosporine (CyA) to treat pre-
sumed rejection. Note resolution of azotemia during 
ORTHOCLONE OKT3 therapy. Note cyclosporine was 
given at first by both IV (dark shading) and oral (no 
shading) routes. Abbreviation: TBIL. total bilirubin; 
SGOT. serum glutamic-oxaloacetic transaminase. Solid 
bars for steroid bolus ~ methylprednisolone IV; open 
bars - hydrocortisone IV. 
one third had no response; the rest had a 
partial response (Table 1). 
Morbidity and mortality are summarized in 
Table 2. No deaths were caused by ORTHO-
CLONE OKT3. One patient had an anaphy-
lactoid reaction, which may have been caused 
by fluid overload. In patients with extrarenal 
transplants, including liver and heart recip-
ients, dialysis may not be as effective in re-
ducing fluid overload as in renal recipients. 
Overall mortality was low, considering that 
previous treatment with steroids had failed in 
these patients. 
Long-term graft function in liver recipients 
is shown in Table 1. Overall, 71 % of these 
patients had a functioning graft after an aver-
age follow-up of 7 months. This is a significant 
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Table 2. Morbidity and Mortality of Patients Treated 
With ORTHOCLONE OKT3 
Liver Kidney 
Recipients Recipients 
(%) (%) 
Morbidity 
Fever 75 80 
Hemodynamic instability 62 60 
Dyspnea 32 20 
Chills 28 70 
Anaphylactoid reaction 2 0 
Infections: Major 15 a 
Minor 56 40 
Mortality 
Overall 23 0 
Group 1 33 
Group 2 18 
Group 3 17 
improvement for a patient population which 
for the most part had not responded to steroid 
therapy. 
The rate of rerejection was low in these liver 
recipients as it had been in our kidney recip-
ients. In this protocol cyclosporine treatment 
was not discontinued during treatment with 
ORTHOCLONE OKT3. It is during the 
ORTHOCLONE OKT3 treatment period 
that basic immunosuppression can be ad-
justed. If this is done effectively to mainte-
nance standards, incidence of later recurrent 
rejection will be small, and maximum poten-
tial of ORTHOCLONE OKT3 will be real-
ized. 
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Serologic studies have shown that more 
than half of ORTHOCLONE OKT3 recip-
ients developed antimurine antibodies during 
therapy. Patients with demonstrable antimu-
rine antibodies from a first treatment were not 
retreated, although retreatment has been done 
successfully by us and by D.l. Norman (per-
sonal communication Nov, 1985). We have 
avoided re-treating patients who had demon-
strable anti murine antibodies from a first 
treatment. Nevertheless, the fact that so many 
patients develop antibodies to the murine pro-
tein is an argument against using ORTHO-
CLONE OKT3 unless it is absolutely 
needed. 
CONCLUSIONS 
ORTHOCLONE OKT3 in conjunction 
with cyclosporine and steroids appears to be 
an effective immunosuppressive combination 
in achieving reversal of renal and hepatic 
rejection. Long-term graft survival without 
excessive recurrent rejection episodes has 
been achieved. 
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